Pharmaceutical Technology
SEPTEMBER 20, 2024
In this issue: Solving adherence issues with prodrugs, examining whether PBMs are to blame for high drugs prices in the US, developing vaccines for Disease X, and more.
Bio Pharma Dive
SEPTEMBER 20, 2024
The decision against Syfovre’s approval follows efforts by Apellis to have reviewers reevaluate clinical evidence multiple times and, according to an analyst, will lead to a restructuring of the company’s operations in Europe.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
SEPTEMBER 20, 2024
The growth of AI in the healthcare sector is already having real-world impacts and promises a step-change in future care.
Bio Pharma Dive
SEPTEMBER 20, 2024
A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Pharmaceutical Technology
SEPTEMBER 20, 2024
The biotech has secured $65m in a Series A funding round led by Cormorant Asset Management and other investors.
Bio Pharma Dive
SEPTEMBER 20, 2024
The agency brought action against Caremark, Express Scripts and Optum Rx on Friday, and warned that all drug manufacturers “should be on notice” as well.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Fierce Pharma
SEPTEMBER 20, 2024
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with the progressive disease suddenly have two new options, with more likely o | Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. With the nod, Dupixent becomes the first biologic treatment for COPD patients in the U.S.
Pharmaceutical Technology
SEPTEMBER 20, 2024
After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS patients.
pharmaphorum
SEPTEMBER 20, 2024
Astellas is ready to launch its first digital health product in the US, called Digitiva, which provides at-home monitoring of people with heart failure
Pharmaceutical Technology
SEPTEMBER 20, 2024
Pharmaceutical Technology has listed the leading pharmaceutical packaging companies and containment solutions suppliers. Download for free.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Fierce Pharma
SEPTEMBER 20, 2024
The hits just keep on coming for Bristol Myers Squibb staffers amid the company's cost-savings program. | Bristol Myers Squibb is laying off an additional 79 staffers in Lawrenceville, New Jersey. The cuts will be effective between Dec. 12 and May 30 of next year and are part of BMS's $1.5 billion cost reduction program.
Pharmaceutical Technology
SEPTEMBER 20, 2024
The Outsourcing in Clinical Trials New England conference will gather pharma experts to discuss the current clinical trial landscape.
pharmaphorum
SEPTEMBER 20, 2024
J&J's target of $5bn in sales for Rybrevant has moved a step closer, after an FDA approval for second-line treatment of EGFR+ NSCLC
Pharmaceutical Technology
SEPTEMBER 20, 2024
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended an update to Novo Nordisk’s Wegovy label.
Fierce Pharma
SEPTEMBER 20, 2024
AstraZeneca has just scored big on the quest to make routine vaccinations less of a hassle. | The FDA signed off on AstraZeneca's influenza vaccine FluMist for self-administration by adults up to 49 years old and for administration by a parent or caregiver in kids between the ages of 2 and 17. With the green light, FluMist is now the only flu vaccine in the U.S. patients can give to themselves.
Pharmaceutical Technology
SEPTEMBER 20, 2024
The NHS England has announced the routine commissioning of Daiichi Sankyo's quizartinib for acute myeloid leukaemia (AML).
Fierce Pharma
SEPTEMBER 20, 2024
Approvals are coming fast and furious for Johnson & Johnson’s Rybrevant as it is lining up to challenge the dominance of AstraZeneca’s Tagrisso in non-small cell lung cancer (NSCLC). | Approvals are coming fast and furious for Johnson & Johnson’s Rybrevant as it is lining up to challenge the dominance of AstraZeneca’s Tagrisso in non-small cell lung cancer (NSCLC).
pharmaphorum
SEPTEMBER 20, 2024
Discover five effective patient travel strategies to improve diversity in clinical research enrolment. Learn how to enhance inclusivity and representation in your research studies.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Fierce Pharma
SEPTEMBER 20, 2024
Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been left in the cold once again. | Europe’s Committee for Medicinal Products for Human Use has confirmed its negative stance on pegcetacoplan in geographic atrophy, an advanced form of age-related macular degeneration that can lead to blindness.
BioPharma Reporter
SEPTEMBER 20, 2024
Dandelion Health used its new clinical AI marketplace to analyze real-world data, showing that GLP-1 drugs may help prevent cardiovascular disease (CVD) for a seven times larger population than previously researched.
Fierce Pharma
SEPTEMBER 20, 2024
For Zevra Therapeutics and its rare neurodegenerative disease med arimoclomol, the second time’s the charm. | The FDA approved Zevra’s arimoclomol capsules to treat the rare lysosomal storage disorder Niemann-Pick disease type C in conjunction with Johnson & Johnson’s enzyme inhibitor miglustat. Arimoclomol, which will fly under the brand name Miplyffa, is now the first FDA-approved therapy for NPC.
Intouch Solutions
SEPTEMBER 20, 2024
Predictive analytics is revolutionizing healthcare marketing by leveraging AI to make data-driven decisions. In this POV, we explore how the use of predictive models enhances engagement by targeting the right audiences, optimizing marketing strategies and best utilizing marketing dollars. We showcase real-world applications where AI-powered predictive analytics has led to significant increases in marketing effectiveness and patient care.
Fierce Pharma
SEPTEMBER 20, 2024
Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated multiple myeloma. That changed Friday. | Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated multiple myeloma. That changed Friday.
pharmaphorum
SEPTEMBER 20, 2024
Job losses loom at Achilles as TIL therapy platform is cut Phil.
Fierce Pharma
SEPTEMBER 20, 2024
Fierce Pharma Asia—Merck's collabs with Daiichi, Eisai deliver readouts; Granules hit with FDA manufacturing observations aliu Fri, 09/20/2024 - 09:21
Pharmaceutical Commerce
SEPTEMBER 20, 2024
In an interview with Pharma Commerce Editor Nicholas Saraceno, Kevin MacDonald, Bluesight’s Co-founder and CEO, discusses why mitigating the impact of rising costs is imperative, while explaining the benefit of advanced analytics tools.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Crucial Data Soutions
SEPTEMBER 20, 2024
The Challenge of Device Provisioning in Clinical Trials In clinical trials, gathering timely and accurate data from patients is essential. The post Simplifying ePRO Data Collection: The Benefits of BYOD with TrialKit appeared first on Crucial Data Solutions.
Pharmaceutical Commerce
SEPTEMBER 20, 2024
A study examines if this PCP-large health system dynamic impacts patient outcomes.
Drug Channels
SEPTEMBER 20, 2024
Today’s guest post comes from Josh Marsh, Vice President and General Manager, Sonexus™ Access and Patient Support at Cardinal Health Josh discusses challenges manufacturers may face when outsourcing patient support programs. He outlines a process that smoothly transitions hubs and minimizes disruptions for patients and healthcare providers. To learn more, download the 3-step guide to patient hub transitions.
XTalks
SEPTEMBER 20, 2024
Chimeric antigen receptor T-cell therapy (CAR T) has provided substantial benefit to patients with certain hematological malignancies and has significant opportunity for growth. As of 2024, the global CAR T-cell therapy market is valued at $4.6 billion and is projected to reach $15.2 billion by 2035. Despite this, CAR T-cell therapies are currently limited to treating B-cell malignancies, and most patients do not achieve progression-free survival.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
130 
Let's personalize your content